Evaluation of SHR-1210 in Combination with Apatinib for Treating BRAF-Negative Mucosal Melanoma: Insights on Efficacy, Safety, and Precision Medicine Applications

1

SHR-1210 combined with Apatinib was evaluated for advanced BRAF-negative mucosal melanoma in a phase II clinical trial.
2

The disease control rate (DCR) was 100%, but the objective response rate (ORR) was 0% among the 13 enrolled patients.
3

The estimated median overall survival (OS) was 29.9 months, while the median progression-free survival (PFS) was 5.17 months.
4

Common adverse effects included hand and foot induration, with one case of severe liver dysfunction and hypertension.
5

The study suggests potential for this combination therapy, but emphasizes the need for larger trials to confirm findings.

Frontiers In Immunology

by Yong Zhang, Ting Wang, An-Qi Lyu, Fang Zhang, Fang-Hui Li, Ling-Di Zhao, Zi-Bing Wang, Yi-Man Shang, Bao-Zhen Ma, Xiao-Qun Dong, Quan-Li Gao
April 21, 2026

1